Get the Stockscreener App
21.52
0.74%
-0.06
Viridian Therapeutics Inc stock is traded at $21.52, with a volume of 7,742.
It is down -0.74% in the last 24 hours and up +17.66% over the past month.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
See More
Previous Close:
$21.58
Open:
$21.53
24h Volume:
7,742
Relative Volume:
0.01
Market Cap:
$1.76B
Revenue:
$305.00K
Net Income/Loss:
$-328.98M
P/E Ratio:
-5.6188
EPS:
-3.83
Net Cash Flow:
$-309.60M
1W Performance:
+10.90%
1M Performance:
+17.66%
6M Performance:
+72.17%
1Y Performance:
-8.41%
1-Day Range:
$21.40
$21.62
1-Week Range:
$18.86
$21.72
52-Week Range:
$9.90
$27.20
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Name
Viridian Therapeutics Inc
Sector
Industry
Phone
617.272.4600
Address
221 CRESCENT STREET, WALTHAM
Compare VRDN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
21.52 | 1.76B | 305.00K | -328.98M | -309.60M | -3.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.18 | 100.41B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
455.55 | 59.77B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.04 | 59.59B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
778.21 | 45.14B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
337.43 | 37.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-25-25 | Resumed | Jefferies | Buy |
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-25-24 | Initiated | TD Cowen | Buy |
| Sep-11-24 | Reiterated | Needham | Buy |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| May-09-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| May-09-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-14-23 | Initiated | BTIG Research | Buy |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| May-30-23 | Initiated | RBC Capital Mkts | Outperform |
| Apr-17-23 | Initiated | Wells Fargo | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Dec-19-22 | Initiated | Cowen | Outperform |
| Dec-19-22 | Initiated | Needham | Buy |
| Dec-16-22 | Initiated | Credit Suisse | Outperform |
| Dec-01-22 | Initiated | H.C. Wainwright | Buy |
| Jun-23-22 | Initiated | B. Riley Securities | Buy |
| Nov-18-21 | Initiated | SVB Leerink | Outperform |
| Oct-12-21 | Initiated | Evercore ISI | Outperform |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Viridian Therapeutics Inc Stock (VRDN) Latest News
Real time alert setup for Viridian Therapeutics Inc. performanceLong Setup & Technical Entry and Exit Alerts - newser.com
How Viridian Therapeutics Inc. stock reacts to bond yields2025 Year in Review & Technical Confirmation Trade Alerts - newser.com
Is Viridian Therapeutics Inc. (1S1) stock protected from inflationWeekly Trade Review & Safe Entry Momentum Stock Tips - newser.com
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Is Viridian Therapeutics Inc. stock dividend yield sustainableJuly 2025 Update & High Yield Stock Recommendations - newser.com
Will Viridian Therapeutics Inc. (1S1) stock beat growth indexesWeekly Stock Summary & Safe Swing Trade Setup Alerts - newser.com
Is Viridian Therapeutics Inc a good long term investmentHigh Frequency Trading Trends & In-Depth Analyst Ratings Explained Simply - earlytimes.in
Is Viridian Therapeutics Inc. stock safe for conservative investors2025 Performance Recap & Real-Time Volume Analysis - newser.com
Viridian Therapeutics: De-Risked Leadership In Thyroid Eye Disease (NASDAQ:VRDN) - Seeking Alpha
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $37.78 Consensus Target Price from Analysts - MarketBeat
Viridian Therapeutics, Inc. (VRDN) Stock Analysis: Potential 93.73% Upside Amid Promising Clinical Trials - DirectorsTalk Interviews
A Look at Viridian Therapeutics’s Valuation Following Completion of Pivotal Phase III Trial Enrollment for VRDN-003 - Sahm
Dividend Watch: Can Viridian Therapeutics Inc. expand its profit marginsMarket Movers & Consistent Profit Focused Trading Strategies - خودرو بانک
Insider Trends: Is Viridian Therapeutics Inc stock a good pick for beginnersJobs Report & AI Optimized Trade Strategies - خودرو بانک
Is Viridian Therapeutics Inc. forming a reversal pattern2025 Year in Review & Momentum Based Trading Ideas - newser.com
Will Viridian Therapeutics Inc benefit from geopolitical trendsJuly 2025 EndofMonth & High Win Rate Trade Tips - خودرو بانک
VIX Spike: Should I hold or sell Viridian Therapeutics Inc nowTrade Ideas & Consistent Return Investment Signals - خودرو بانک
Aug Big Picture: What is Viridian Therapeutics Incs 5 year growth outlookEarnings Recap Report & AI Enhanced Trading Signals - خودرو بانک
Building trade automation scripts for Viridian Therapeutics Inc.Market Risk Summary & Technical Buy Zone Confirmations - newser.com
Quarterly Trades: Will Viridian Therapeutics Inc benefit from geopolitical trendsWeekly Trend Summary & Fast Entry Momentum Alerts - خودرو بانک
VIX Spike: What is Viridian Therapeutics Incs 5 year growth outlookSwing Trade & Technical Pattern Based Signals - khodrobank.com
Is Viridian Therapeutics Inc. meeting your algorithmic filter criteriaJuly 2025 Sector Moves & Real-Time Market Sentiment Alerts - newser.com
Detecting support and resistance levels for Viridian Therapeutics Inc.Trade Entry Report & Step-by-Step Swing Trade Plans - newser.com
Viridian Therapeutics Inc. stock prediction for this weekWeekly Stock Summary & Community Consensus Stock Picks - newser.com
Risk Analysis: What is the target price for Viridian Therapeutics Inc stockPrice Action & Reliable Breakout Forecasts - خودرو بانک
Published on: 2025-09-17 20:01:22 - خودرو بانک
Does Viridian Therapeutics Inc. qualify in momentum factor screeningQuarterly Performance Summary & High Accuracy Swing Entry Alerts - newser.com
Hedge Fund Bets: What is CGONs 5 year growth outlookSwing Trade & Fast Entry High Yield Stock Tips - خودرو بانک
Aug Wrap: Should I add Viridian Therapeutics Inc. stock to my portfolio2025 Bull vs Bear & Proven Capital Preservation Methods - خودرو بانک
BTIG reiterates Buy rating on Viridian Therapeutic stock as trials complete enrollment - Investing.com Canada
Breakouts Watch: Can Viridian Therapeutics Inc withstand a market correctionWeekly Investment Recap & Fast Gain Stock Tips - خودرو بانک
Decliners Report: Can Viridian Therapeutics Inc. disrupt its industry2025 Stock Rankings & Low Risk High Reward Trade Ideas - خودرو بانک
Viridian Therapeutics, Inc. $VRDN Shares Sold by Alliancebernstein L.P. - MarketBeat
Weekly Recap: What are the future prospects of Viridian Therapeutics IncJuly 2025 Action & Free High Accuracy Swing Entry Alerts - خودرو بانک
Viridian Therapeutics: Promising Pipeline and Strategic Advancements Justify Buy Rating - TipRanks
Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates - BioSpace
Entry Recap: Can Viridian Therapeutics Inc. lead its sector in growthQuarterly Investment Review & Expert Approved Momentum Trade Ideas - خودرو بانک
Momentum Shift: Is BCGWW undervalued by DCF analysisJuly 2025 Reactions & Low Drawdown Momentum Ideas - خودرو بانک
Published on: 2025-09-15 21:50:00 - خودرو بانک
Viridian Therapeutics completes enrollment in REVEAL-1 and REVEAL-2 clinical trials for VRDN-003 - Ophthalmology Times
Viridian Therapeutics announces completion of enrollment in both Reveal clinical trials and positive portfolio updates - MarketScreener
Viridian Therapeutics Announces Completion Of Enrollment In Both Reveal Clinical Trials And Positive Portfolio Updates - TradingView
Viridian Therapeutics (VRDN) Completes Enrollment for Key Phase 3 Trials - GuruFocus
Hedge Fund Bets: Can Viridian Therapeutics Inc. expand its profit margins2025 Top Decliners & Daily Volume Surge Signals - خودرو بانک
Octagon Capital Advisors LP Reduces Stake in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Exome Asset Management LLC Invests $2.93 Million in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Yiheng Capital Management L.P. Cuts Stock Position in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Adage Capital Partners GP L.L.C. Sells 555,414 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat
Invesco Ltd. Acquires 14,672 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian Therapeutics Inc Stock (VRDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
1.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):